整理 | GLP1减重宝典内容团队 正是基于这一信号，礼来已率先完成战略卡位。2025 年 10 月，礼来为其 GLP-1/GIP 双受体激动剂 Brenipatide 启动了针对酒精使用障碍的三 期临床试验，预计 2028 年完成主要数据读取。更值得注意的是，该药物并未被定位为单一适应症产品，而是同步推进抑郁症、双相情感障碍 等精神疾病方向，礼来的目标显然是构建一款覆盖代谢、情绪与成瘾行为的多适应症平台型药物。 在这样的背景下，Baseline 的入场显得极具针对性。这家初创公司尚未披露完整融资规模，但其公布的信息显示，BT-001 的研发路径已获得 FDA 认可，并计划在今年内同步启动两项针对酒精使用障碍的三期临床试验，在时间轴上紧追礼来。与此同时，Baseline 还计划于今年第三季 度推进 BT-001 在可卡因和甲基苯丙胺成瘾领域的 II 期或 III 期临床研究，试图以更激进的适应症扩展速度，建立横跨多种成瘾行为的竞争护 城河。 当 GLP-1 药物仍在减肥与降糖赛道激烈缠斗时，一场更隐秘、但潜在规模更大的竞争，已在成瘾治疗领域悄然展开。1 月 27 日，美国旧金山 初创公司 Baseline T ...

Core Viewpoint - The article discusses the potential effects of GLP-1 receptor agonists, commonly used for weight loss, on alcohol consumption and its effects, suggesting that these medications may reduce the sensation of intoxication and drinking desire [5][10]. Summary by Sections What are GLP-1 Drugs? - GLP-1 drugs, such as semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro), mimic natural hormones that regulate blood sugar and appetite [7]. Research Findings - A study involving 20 obese adults found that those taking GLP-1 drugs experienced a slower onset of intoxication and reduced feelings of drunkenness compared to those not on the medication. This effect is attributed to delayed gastric emptying, which slows the absorption of alcohol into the bloodstream [8]. - Participants on GLP-1 drugs reported lower drinking desires, and the study indicated that the reduced intoxication was not due to nausea or blood sugar changes, suggesting a unique mechanism of action through the gut [8]. Limitations and Future Research Directions - The study is a small preliminary trial without random assignment, focusing solely on obese patients. More extensive research is needed to determine the effectiveness, long-term effects, and optimal dosages for blood sugar control and alcohol reduction [9]. - Experts caution that the findings do not establish causation and highlight the need for future studies to track overall alcohol intake and drinking desires to assess potential compensatory behaviors [9]. Potential for Addiction Treatment - Emerging data suggest that GLP-1 drugs may play a role in addiction treatment, as GLP-1 receptors influence reward signals related to food, alcohol, and nicotine. If validated in larger studies, these drugs could bridge endocrinology and behavioral health [10].

Core Insights - The article discusses a recent study indicating that GLP-1 receptor agonists, popular weight loss medications, may not only reduce waist circumference and control blood sugar but also potentially diminish the effects of alcohol [5][8]. Summary by Sections What are GLP-1 Drugs? - GLP-1 drugs, such as Semaglutide (Ozempic and Wegovy) and Tirzepatide (Mounjaro), mimic natural hormones that regulate blood sugar and appetite [7]. Study Results - The study involved 20 obese adults, half of whom had taken GLP-1 drugs for at least four weeks. Participants consumed a measured amount of alcohol after fasting, aiming for a breath alcohol concentration of 0.08. Those on GLP-1 drugs reported feeling less intoxicated and experienced a delayed onset of alcohol effects due to slower gastric emptying [8]. - Participants taking GLP-1 drugs exhibited lower drinking desires, and nausea and blood sugar changes were similar between both groups, suggesting that reduced intoxication was not due to discomfort [8]. Limitations and Future Research Directions - The study is a small-scale preliminary trial without random assignment, focusing solely on obese patients. More research is needed to determine the drugs' effectiveness, long-term effects, and optimal dosages for blood sugar control and alcohol reduction [9]. - Experts caution that the findings do not establish causation and highlight the need for future studies to track overall alcohol consumption and drinking desires to assess potential compensatory behaviors [9]. Potential in Addiction Treatment - Emerging data suggest that GLP-1 drugs may play a role in addiction treatment, as GLP-1 receptors influence reward signals for food, alcohol, and nicotine. If validated in larger studies, these drugs could bridge endocrinology and behavioral health, shifting public focus from weight loss to broader medical applications [10].

Core Viewpoint - The article discusses the potential effects of GLP-1 receptor agonists, popular weight loss medications, on alcohol consumption and its effects, suggesting that these drugs may reduce the impact of alcohol on the body and decrease drinking desire [5][10]. Summary by Sections What are GLP-1 Drugs? - GLP-1 drugs, such as semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro), mimic natural hormones that regulate blood sugar and appetite [7]. Research Findings - A study involving 20 obese adults found that those taking GLP-1 drugs experienced a delayed sensation of intoxication and lower drinking desire compared to those not on the medication. The drugs appeared to slow gastric emptying, which in turn reduced the rate at which alcohol entered the bloodstream [8]. - Participants in the GLP-1 group reported similar levels of nausea and blood sugar changes as the control group, indicating that the reduced intoxication was not due to discomfort [8]. Limitations and Future Research Directions - The study was small and preliminary, lacking random assignment and only involving obese patients. More extensive research is needed to determine the effectiveness, long-term effects, and optimal dosages of these drugs for blood sugar control and alcohol reduction [9]. - Experts caution that the reduced sensation of intoxication could lead to increased alcohol consumption, highlighting the need for future studies to track overall alcohol intake and drinking desires [9]. Potential for Addiction Treatment - Emerging data suggest that GLP-1 drugs may play a role in addiction treatment, as GLP-1 receptors influence reward signals related to food, alcohol, and nicotine. If validated in larger studies, these drugs could bridge the gap between endocrinology and behavioral health [10].